Shares of Zelira Therapeutics Limited (OTCMKTS:ZLDAF – Get Free Report) were down 23.1% on Thursday . The stock traded as low as $0.22 and last traded at $0.22. Approximately 100 shares changed hands during mid-day trading, a decline of 60% from the average daily volume of 250 shares. The stock had previously closed at $0.29.
Zelira Therapeutics Price Performance
The business has a 50 day simple moving average of $0.30 and a 200-day simple moving average of $0.36.
About Zelira Therapeutics
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. The company offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia.
Further Reading
- Five stocks we like better than Zelira Therapeutics
- How to Profit From Growth Investing
- IBM’s AI Offensive: Assessing IBM’s Path to Renewed Growth
- What Are Dividend Contenders? Investing in Dividend Contenders
- Rockwell Automation: Tailwinds From Onshoring U.S. Production
- How to Plot Fibonacci Price Inflection Levels
- Is Energy Transfer Undervalued or a Value Trap?
Receive News & Ratings for Zelira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zelira Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
